ELYM vs. KPTI, CTMX, VTGN, FGEN, NVCT, RPTX, OPTN, SGMT, CTXR, and COYA
Should you be buying Eliem Therapeutics stock or one of its competitors? The main competitors of Eliem Therapeutics include Karyopharm Therapeutics (KPTI), CytomX Therapeutics (CTMX), Vistagen Therapeutics (VTGN), FibroGen (FGEN), Nuvectis Pharma (NVCT), Repare Therapeutics (RPTX), OptiNose (OPTN), Sagimet Biosciences (SGMT), Citius Pharmaceuticals (CTXR), and Coya Therapeutics (COYA). These companies are all part of the "pharmaceutical preparations" industry.
Karyopharm Therapeutics (NASDAQ:KPTI) and Eliem Therapeutics (NASDAQ:ELYM) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, community ranking, risk, analyst recommendations, media sentiment, earnings, valuation, profitability and institutional ownership.
Eliem Therapeutics has lower revenue, but higher earnings than Karyopharm Therapeutics. Eliem Therapeutics is trading at a lower price-to-earnings ratio than Karyopharm Therapeutics, indicating that it is currently the more affordable of the two stocks.
Karyopharm Therapeutics currently has a consensus target price of $5.67, suggesting a potential upside of 412.82%. Given Eliem Therapeutics' higher possible upside, equities research analysts clearly believe Karyopharm Therapeutics is more favorable than Eliem Therapeutics.
In the previous week, Eliem Therapeutics had 1 more articles in the media than Karyopharm Therapeutics. MarketBeat recorded 2 mentions for Eliem Therapeutics and 1 mentions for Karyopharm Therapeutics. Eliem Therapeutics' average media sentiment score of 1.34 beat Karyopharm Therapeutics' score of 0.63 indicating that Karyopharm Therapeutics is being referred to more favorably in the media.
Eliem Therapeutics has a net margin of 0.00% compared to Eliem Therapeutics' net margin of -97.99%. Eliem Therapeutics' return on equity of 0.00% beat Karyopharm Therapeutics' return on equity.
66.4% of Karyopharm Therapeutics shares are owned by institutional investors. Comparatively, 69.8% of Eliem Therapeutics shares are owned by institutional investors. 3.3% of Karyopharm Therapeutics shares are owned by insiders. Comparatively, 4.7% of Eliem Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Karyopharm Therapeutics has a beta of 0.03, meaning that its share price is 97% less volatile than the S&P 500. Comparatively, Eliem Therapeutics has a beta of 0.51, meaning that its share price is 49% less volatile than the S&P 500.
Karyopharm Therapeutics received 516 more outperform votes than Eliem Therapeutics when rated by MarketBeat users. Likewise, 72.02% of users gave Karyopharm Therapeutics an outperform vote while only 56.25% of users gave Eliem Therapeutics an outperform vote.
Summary
Karyopharm Therapeutics beats Eliem Therapeutics on 9 of the 16 factors compared between the two stocks.
Get Eliem Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ELYM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ELYM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Eliem Therapeutics Competitors List
Related Companies and Tools
